Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Postpartum disease activity and breastfeeding in multiple sclerosis revisited.
Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
2015 Annual Meeting of the Consortium of the Multiple Sclerosis Centers
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
Episode 59 with Dr. Helmut Butzkueven on the new MS Brain Health initiative
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
Improving the translational hit of experimental treatments in multiple sclerosis.
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
Episode 44 with Dr. Monika Bradl on an animal model for neuromyelitis optica (NMO)
FOCiS 2015 Meeting: Immunology by the Bay
Episode 42 with Dr. Lawrence Steinman on amyloid in experimental autoimmune encephalomyelitis
Parenteral Dilantin®
International Society for Neurovascular Disease (ISNVD)
Episode 62 with Dr. Ellen Mowry on vitamin D and caloric restriction for MS
Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis
Zist Daru, ZIFERON
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
Remyelination in experimental models of toxin-induced demyelination.
Episode 61 with Dr. Yanming Wang on molecular imaging of the myelin sheathing of axons
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec.

Pages